Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.57 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.57 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941678 | 0.82 | CA12 (0.53) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL1052785 | 0.82 | CA12 (0.53) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL9096468 | 0.78 | CA12 (0.46) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL17637285 | 0.76 | HTR2C (0.37) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL12604116 | 0.74 | PDE3B (0.36) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL29967380 | 0.72 | BRPF1 (1.00) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL248619 | 0.72 | BRPF1 (1.00) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL14584044 | 0.72 | SLC6A2 (0.45) | CA12CA9BRD4BRPF1KAT2B | |
| Hydrochloric Acid SCHEMBL30419636 | 0.71 | BRPF1 (0.96) | CA12CA9BRD4BRPF1KAT2B | |
| Hydrochloric Acid SCHEMBL1236989 | 0.71 | BRPF1 (0.96) | CA12CA9BRD4BRPF1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252473-B2 | Preparation methods of quinolone compounds and intermediates thereof | Chongqing University of Arts and Sciences (CN) | 2025-03-18 | — | — | US | disclosed |
| US-20240400522-A1 | PREPARATION METHODS OF QUINOLONE COMPOUNDS AND INTERMEDIATES THEREOF | Chongqing University of Arts and Sciences (CN) | 2024-12-05 | — | — | US | disclosed |
| US-12029683-B2 | Ocular implant and delivery system | ALCON INC. (CH) | 2024-07-09 | — | — | US | disclosed |
| US-20240207091-A1 | DRUG DELIVERY IMPLANTS WITH BI-DIRECTIONAL DELIVERY CAPACITY AND METHODS OF USING SAME | GLAUKOS CORP (US) | 2024-06-27 | — | — | US | disclosed |
| US-11992551-B2 | Implants with controlled drug delivery features and methods of using same | GLAUKOS CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4371535-A2 | OCULAR IMPLANT | Alcon Inc. (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20240108219-A1 | INTRAOCULAR PHYSIOLOGICAL SENSOR | GLAUKOS CORPORATION | 2024-04-04 | — | — | US | disclosed |
| EP-3755287-B1 | OCULAR IMPLANT | ALCON INC (CH) | 2024-04-03 | — | — | EP | disclosed |
| US-11944573-B2 | System and method for delivering multiple ocular implants | GLAUKOS CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-11938058-B2 | Ocular implant and delivery system | ALCON INC. (CH) | 2024-03-26 | — | — | US | disclosed |
| US-20130253528-A1 | SYSTEM AND METHOD FOR DELIVERING MULTIPLE OCULAR IMPLANTS | GLAUKOS CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130090534-A1 | INTRAOCULAR PHYSIOLOGICAL SENSOR | GLAUKOS CORPORATION | 2013-04-11 | — | — | US | disclosed |
| WO-2013040079-A1 | INTRAOCULAR PHYSIOLOGICAL SENSOR | DOSE MEDICAL CORPORATION (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012158910-A2 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120165933-A1 | UVEOSCLERAL DRUG DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME | DOSE MEDICAL CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012071476-A2 | DRUG ELUTING OCULAR IMPLANT | HAFFNER DAVID (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120078362-A1 | DRUG ELUTING OCULAR IMPLANT | DOSE MEDICAL CORPORATION (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2432420-A1 | DRUG ELUTING OCULAR IMPLANT | Dose Medical Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135369-A1 | DRUG ELUTING OCULAR IMPLANT | DOSE MEDICAL CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010093945-A2 | UVEOSCLERAL DRUG DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME | GLAUKOS CORPORATION (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400522-A1 | PREPARATION METHODS OF QUINOLONE COMPOUNDS AND INTERMEDIATES THEREOF | NQO2, MRPL21, RECQL | CA12 3613/4885CA9 3870/4885BRD4 2009/4885 |
| US-12252473-B2 | Preparation methods of quinolone compounds and intermediates thereof | NQO2, MRPL21, RECQL | CA12 3613/4885CA9 3870/4885BRD4 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.